翱捷科技股份有限公司2025 年半年度报告摘要 公司代码：688220 公司简称：翱捷科技 翱捷科技股份有限公司 翱捷科技股份有限公司2025 年半年度报告摘要 第一节 重要提示 规划，投资者应当到 www.sse.com.cn 网站仔细阅读半年度报告全文。 详见公司《2025 年半年度报告》第三节"管理层讨论与分析"之"四、风险因素"所述内容，请 投资者予以关注。 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 无 □适用 √不适用 翱捷科技股份有限公司2025 年半年度报告摘要 第二节 公司基本情况 公司股票简况 公司股票简况 股票种类 股票上市交易所 股票简称 股票代码 变更前股票简 称 A股 上海证券交易所科 翱捷科技 688220 不适用 创板 公司存托凭证简况 □适用 √不适用 联系人和联系方式 联系人和联系方式 董事会秘书（信息披露境内代 证券事务代表 表） 姓名 韩旻 白伟扬 电话 021-60336588*1188 021-60336588*1188 办公地址 中国（上海）自由贸易试验区 中国（上海）自由贸易试验区 科苑路399号10幢8层（名义楼 科苑路399号10幢8层（名 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688265 证券简称：南模生物 公告编号：2025-047 上海南方模式生物科技股份有限公司 关于持股5%以上股东及其一致行动人权益变动触及1%整数倍的提示性公告 信息披露义务人上海浦东新兴产业投资有限公司保证向本公司提供的信息真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 2.信息披露义务人信息 ■ 3.一致行动人信息 ■ 重要内容提示： ■ ● 本次权益变动为上海南方模式生物科技股份有限公司（以下简称"公司"或"上市公司"）股东增持股份 所致，不触及要约收购，不会导致上市公司控股股东、实际控制人发生变化。 一、信息披露义务人及其一致行动人的基本信息 1.身份类别 ■ 5、公司将持续关注股东权益变动情况，严格按照相关法律法规的要求及时履行信息披露义务，敬请广 大投资者注意投资风险。 特此公告。 二、权益变动触及1%整数倍的基本情况 2025年8月13日，公司收到股东上海浦东新兴产业投资有限公司（以下简称"浦东新产业"）发来的《关 于南模生物权益变动触及1%整数倍的告知函 ...

Core Viewpoint - Nanmo Biological (688265.SH) has received a notification from its shareholder, Shanghai Pudong New Industry Investment Co., Ltd., regarding a change in equity that has reached a 1% integer multiple [1] Summary by Relevant Sections - Shareholder Activity - Shanghai Pudong New Industry increased its holdings in Nanmo Biological by acquiring a total of 1,096,027 unrestricted circulating shares through centralized bidding from August 5, 2025, to August 13, 2025 [1] - The combined shareholding of Shanghai Pudong New Industry and its concerted action party, Suzhou Haiwang Hezhong No. 1 Equity Investment Partnership (Limited Partnership), rose from 17.10% to 18.50% [1]

Core Insights - Fudan Zhangjiang (688505.SH) released its semi-annual report for 2025 on August 13, 2025, indicating significant institutional investment in the company [1] Institutional Holdings - As of August 12, 2025, four institutional investors disclosed holdings in Fudan Zhangjiang A-shares, totaling 306 million shares, which represents 29.52% of the company's total equity [1] - The institutional investors include New Venture Phase II Venture Capital, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai Pudong New Area Emerging Industry Investment Co., Ltd., and Hong Kong Central Clearing Limited [1] - Compared to the previous quarter, the total institutional holding percentage increased by 0.28 percentage points [1] Public Fund and Foreign Investment - In the current period, one public fund was disclosed, which is the Wanji Pharmaceutical Quantitative Stock Selection Mixed Initiation A [1] - Regarding foreign investment, one new foreign institution was disclosed in the current period, namely Hong Kong Central Clearing Limited [1]

证券代码：688265 证券简称：南模生物 公告编号：2025-046 上海南方模式生物科技股份有限公司 关于持股5%以上股东协议转让股份过户完成的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 2025年6月25日，上海南方模式生物科技股份有限公司（以下简称"公司"或"南模生物"）持股5%以上 股东深圳前海海润荣丰投资合伙企业（有限合伙）（以下简称"海润荣丰"）、股东康君投资管理（北 京）有限公司－北京康君宁元股权投资合伙企业（有限合伙）（以下简称"康君宁元"，由基金管理人康 君投资管理（北京）有限公司代表）、股东上海张江集体资产投资经营管理有限公司（以下简称"张江 集体"）与苏州海望合纵一号股权投资合伙企业（有限合伙）（以下简称"海望合纵"）分别签署了《关 于上海南方模式生物科技股份有限公司之股份转让协议》（以下简称"《股份转让协议》"），海润荣丰 拟通过协议转让的方式将其持有的4,650,318股公司股份以27.369元/股的价格转让给海望合纵，转让股 份占公司总股本的5.96%； ...

证券代码：688265 证券简称：南模生物 公告编号：2025-045 上海南方模式生物科技股份有限公司 关于持股 5%以上股东及其一致行动人权益变动触及 ? 本次权益变动为上海南方模式生物科技股份有限公司（以下简称"公司" 或"上市公司"）股东增持股份所致，不触及要约收购，不会导致上市公司控股股 东、实际控制人发生变化。 信息披露义务人上海浦东新兴产业投资有限公司保证向本公司提供 的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信 息一致。 ? 截至本公告披露日，苏州海望合纵一号股权投资合伙企业（有限合伙） （以下简称"海望合纵"）在本次权益变动前通过协议转让方式受让的 8,679,727 股公司股份尚未在中国证券登记结算有限责任公司上海分公司办理完成股份转 让过户登记手续，交易能否最终完成尚存在不确定性，敬请广大投资者注意投资 风险。 一、 信息披露义务人及其一致行动人的基本信息 □控股股东/实际控制人及其一致行动人 投资者及其一致行动人的身份 重要内容提示： 权益变动方向 比例增加 比例减少□ 权益变动前合计比例 15.00% 权益变 ...

Core Viewpoint - Nanmo Biotechnology (688265.SH) received a notification from its shareholder, Shanghai Pudong New Industry Investment Co., Ltd., regarding a change in equity that triggered a 1% threshold increase in shareholding [1] Group 1 - Shanghai Pudong New Industry increased its holdings in Nanmo Biotechnology by acquiring a total of 1,633,976 unrestricted circulating shares through centralized bidding from July 31, 2025, to August 4, 2025 [1] - The shareholding ratio of Shanghai Pudong New Industry and its concerted action party, Haiwang Hezhong, rose from 15.00% to 17.10% following this transaction [1]

Core Viewpoint - The announcement details a change in shareholding for Shanghai Nanmo Biological Technology Co., Ltd., indicating an increase in shares held by Shanghai Pudong New Industry Investment Co., Ltd. and its concerted action party, without triggering a mandatory takeover or changing the controlling shareholder [1][2]. Summary by Sections Shareholding Changes - Prior to the change, Shanghai Pudong New Industry held 2,160,000 shares, representing 2.77% of the total share capital, while its concerted action party, Suzhou Haiwang Hezong No.1 Equity Investment Partnership, held 8,679,727 shares, or 11.13%. Together, they held 10,839,727 shares, accounting for 13.90% of the total [1][3]. - On July 16, 2025, Pudong New Industry increased its holdings by 854,800 shares, bringing its total to 3,014,800 shares, or 3.87%. The combined holdings of Pudong New Industry and Haiwang Hezong now total 11,694,527 shares, or 15.00%, reaching a 5% integer multiple [2][3]. Funding Source - The funds used for the share increase by Pudong New Industry were sourced entirely from its own capital, confirming the legality of the funding [4]. Compliance and Regulatory Notes - The share transfer of 8,679,727 shares by Haiwang Hezong is pending compliance confirmation from the Shanghai Stock Exchange and must complete the transfer registration with the China Securities Depository and Clearing Corporation [2][3].

Group 1 - The core point of the news is the equity change report regarding Shanghai Southern Model Biotechnology Co., Ltd, where Suzhou Haiwang Hezong No. 1 Equity Investment Partnership (Limited Partnership) is increasing its shareholding in the company [1][2] - The report indicates that the equity change is based on the confidence in the company's future development and long-term investment value recognition [9] - The report outlines that the equity change requires compliance confirmation from the Shanghai Stock Exchange and registration procedures with the China Securities Depository and Clearing Corporation [5][38] Group 2 - The information disclosing party, Suzhou Haiwang Hezong, has not held shares in the company prior to this equity change, while its action partner, Shanghai Pudong New Industry Investment Co., Ltd., held 2,160,000 shares, accounting for 2.77% of the total share capital [12][13] - After the equity change, the information disclosing party will hold 8,679,727 shares, representing 11.13% of the total share capital, while the combined holdings with its action partner will total 10,839,727 shares, or 13.90% of the total share capital [12][13] - The share transfer agreement specifies that the shares will be transferred at a price of 27.369 yuan per share, with the total transfer price amounting to approximately 127.27 million yuan [15][56] Group 3 - The report confirms that the equity change does not trigger a mandatory tender offer and will not lead to changes in the controlling shareholder or actual controller of the company [39] - The report also states that the equity change complies with relevant laws and regulations, including the Securities Law and the Acquisition Measures [39] - The information disclosing party has committed to not reduce its holdings in the company for 12 months following the completion of the share transfer [11]